Response to H1N1 Vaccine in HIV Patients
Author Information
Author(s): Darius Soonawala, Guus F. Rimmelzwaan, Luc B. S. Gelinck, Leo G. Visser, Frank P. Kroon
Primary Institution: Leiden University Medical Center
Hypothesis
Does prior seasonal influenza vaccination influence the immune response to the 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients?
Conclusion
One dose of the H1N1 vaccine induced a high seroprotection rate in HIV-infected patients comparable to healthy controls, with a modest additional effect from a second dose.
Supporting Evidence
- The seroprotection rate for HIV-infected patients was 88% after the first and 91% after the second vaccination.
- Post-vaccination geometric mean titers were lower in HIV-infected patients compared to healthy controls.
- Recent vaccination with seasonal TIV increased the seroprotection rate to pH1N1 from 22% to 49%.
Takeaway
The study shows that HIV patients can respond well to the H1N1 vaccine, especially if they had a flu shot before.
Methodology
This was a single-center prospective cohort study where the H1N1 vaccine was given to HIV-infected patients and healthy controls, and antibody responses were measured at multiple time points.
Potential Biases
Potential bias due to the single-center design and the specific population studied.
Limitations
The study did not confirm influenza infections with respiratory samples, and the generalizability may be limited as most participants were on effective antiretroviral therapy.
Participant Demographics
57 HIV-infected patients (84% male, mean age 52 years) and 44 healthy controls (61% male, mean age 49 years).
Statistical Information
P-Value
0.06
Confidence Interval
95% CI 1.0-2.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website